215 related articles for article (PubMed ID: 22257609)
21. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
22. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin: too much or too little.
Newland A
Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
[TBL] [Abstract][Full Text] [Related]
24. [Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
Matzdorff A; Giagounidis A; Greinacher A; Hiller E; Kiefel V; Müller-Beissenhirtz H; Ostermann H; Rummel M; Sachs UJ; Salama A
Onkologie; 2010; 33 Suppl 3():2-20. PubMed ID: 20484949
[No Abstract] [Full Text] [Related]
25. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.
Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Velázquez-Sánchez-de-Cima S; Zamora-Ortiz G
Hematology; 2013 May; 18(3):175-7. PubMed ID: 23321502
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
27. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
28. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
[TBL] [Abstract][Full Text] [Related]
29. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Francesco R
Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
[No Abstract] [Full Text] [Related]
30. ITP and international guidelines: what do we know, what do we need?
Rodeghiero F; Ruggeri M
Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
[TBL] [Abstract][Full Text] [Related]
31. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
[TBL] [Abstract][Full Text] [Related]
32. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
33. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
34. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
35. Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Audia S; Godeau B; Bonnotte B
Rev Med Interne; 2016 Jan; 37(1):43-9. PubMed ID: 26422785
[TBL] [Abstract][Full Text] [Related]
36. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
Panzer S
Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
[TBL] [Abstract][Full Text] [Related]
38. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
39. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
40. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Aguilar C
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
